Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | ADH1C | P00326 | 3/20 | 0.33 |
| ▸ | ADH1A | P07327 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MC5R | P33032 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240531 | 0.73 | SLC6A2 (0.44) | SLC6A2SLC6A4ADH1CADH1AADH4 | |
| SCHEMBL7248078 | 0.73 | ADH1A (0.47) | SLC6A2SLC6A4ADH1CADH1A | |
| SCHEMBL3851542 | 0.72 | CNR2 (0.55) | TAS2R14CNR1CNR2 | |
| SCHEMBL3855992 | 0.72 | TAS2R14 (0.58) | TAS2R14CNR1CNR2 | |
| SCHEMBL3861362 | 0.71 | TAS2R14 (0.52) | TAS2R14CNR1CNR2 | |
| SCHEMBL3850131 | 0.70 | TAS2R14 (0.44) | TAS2R14CNR1CNR2 | |
| SCHEMBL3855987 | 0.70 | TAS2R14 (0.53) | TAS2R14CNR1CNR2 | |
| SCHEMBL3853114 | 0.70 | TAS2R14 (0.61) | TAS2R14CNR1CNR2 | |
| SCHEMBL14855420 | 0.68 | G6PC1 (0.46) | SLC6A2SLC6A4ADH1CADH1A | |
| SCHEMBL20625943 | 0.68 | CXCR4 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007067817-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | KDM1A 4752/4885TAS2R14 4736/4885SLC6A2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.